Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

Results View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹99.25

prior close

₹96.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-5.2% vs market

Pharmaceuticals peers, median of 157sector+0.0%-5.3% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.5

15m

+1.5

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3-0.1-5.2+0.0-5.3

Next day

-5.3+0.5-5.8-0.1-5.2

-4.8-0.3-4.5-0.9-3.9

-6.3-0.5-5.8-1.3-5.0

-7.3-0.8-6.5-1.6-5.7

-7.2-2.3-4.9-2.3-4.9

-9.4-2.8-6.6-2.9-6.5

15d

-2.8-4.9+2.1-3.6+0.8

+1.8-4.7+6.5-4.4+6.1

-6.8-7.7+0.9-5.6-1.2

-0.3-7.8+7.6-10.7+10.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals Limited has submitted its unaudited financial results for the quarter and half-year ended September 30, 2025 to the NSE Exchange. The filing pertains to Q2 of FY2026 and was made as part of routine quarterly compliance requirements under SEBI LODR regulations. No specific revenue, profit, or margin figures have been disclosed in this headline announcement. Investors should refer to the actual results document for detailed financial performance.

Likely market impact

This is a routine regulatory submission and is unlikely to have an immediate material impact on the stock price. Shareholders should review the detailed results for any significant changes in revenue, profitability, or margins compared to the previous quarter and year-ago period.